The company's share price Addex Therapeutics
Addex is a Swiss biotechnology company specializing in the development of small-molecule drugs. Its share price is driven by news of clinical trials and partnerships with major pharmaceutical companies.
Addex is a Swiss biotechnology company specializing in the development of small-molecule drugs. Its share price is driven by news of clinical trials and partnerships with major pharmaceutical companies.
Addex Therapeutics is a Swiss biopharmaceutical company developing drugs that modulate receptors for the treatment of neurological disorders. We've classified it in the "Neurology" category. The chart below shows how investors assess the risks and prospects in this complex area of medicine.
Addex Therapeutics is a Swiss biopharmaceutical company developing small-molecule drugs that modulate receptors in the central nervous system. Its scientific approach makes it a key component of the GURU.Markets index. The chart below represents the entire market. Find out how Addex compares to it.
Addex Therapeutics Ltd's daily price change reflects the high volatility inherent in biotech companies. This indicator measures the sensitivity to news about clinical trials of its drugs for neurological disorders.
Addex Therapeutics focuses on developing drugs for the treatment of neurological disorders. The biopharmaceutical sector is extremely sensitive to clinical trial data. The chart below shows the average volatility for this niche, providing context for assessing ADXN's price movements relative to its competitors.
Addex is a Swiss biotech company developing drugs for the treatment of neurological diseases. Its shares are driven by news of clinical trials, adding an element of high scientific volatility to the overall market picture.
Addex Therapeutics' year-to-date performance is a story of allosteric modulator development. Its 12-month market cap is entirely dependent on clinical trial data. Partnerships with major companies like Janssen are key confirmation of the potential of its unique platform for developing a new class of drugs.
As an early-stage biotech company, Addex is a high-risk bet on science. Its performance is completely disconnected from the sector and depends on news about clinical trials of its drugs for neurological diseases. Its stock price will reflect the speculative faith of investors.
Addex Therapeutics, focused on developing drugs for neurological disorders, exemplifies the classic biotech model. Its year-over-year market capitalization reflects its high sensitivity to research results. The success or failure of a single drug can trigger explosive growth or decline, defying overall trends.
Addex is a Swiss biopharmaceutical company. Its monthly performance is entirely dependent on progress in its clinical programs and its partnerships with major pharmaceutical companies. News of key research milestones are the main drivers.
Addex Therapeutics Ltd. is a Swiss clinical-stage biopharmaceutical company pioneering the development of small-molecule drugs that modulate receptors rather than block them. The dynamics of its sector, shown in the chart, reflect the risks of R&D. Against this backdrop, it is possible to assess how its unique scientific approach is advancing the treatment of neurological disorders.
Addex Therapeutics is a Swiss biopharmaceutical company. Its NASDAQ shares are driven by clinical trial news rather than U.S. market trends. The chart shows the high volatility typical of biotech companies, whose value is a bet on the success of future drugs.
Addex Therapeutics is a Swiss biopharmaceutical company developing allosteric modulator drugs. Its weekly stock price is volatile and depends on the progress of its clinical programs.
Addex Therapeutics is a Swiss biotech company focused on neuroscience. The chart compares its weekly performance with the sector. How much do its drug development successes and partnerships impact its stock compared to overall biotech trends?
Addex Therapeutics is another biotech company whose stock exists in its own universe, reacting to clinical trial data. The chart clearly demonstrates how its weekly performance is isolated from general market fluctuations, following its own unique scientific trajectory.
Addex Therapeutics' chart tells the story of a new approach to drug development. This Swiss company's market cap reflects investors' faith in its allosteric modulator platform, which enables fine-tuning of receptor function to treat neurological diseases.
Addex Therapeutics is a Swiss biopharmaceutical company specializing in the development of small-molecule drugs that modulate, rather than block, receptors. In the neuroscience segment, its market capitalization reflects the potential for this fine-tuning of brain function. The company's size is a reflection of its partnerships with major pharmaceutical companies and the success of its developments.
Addex Therapeutics is a pioneer in the development of allosteric modulators. How big is this arena? The chart below is a barometer of the neuroscience pharmaceutical sector. Its volatile dynamics reflect the enormous risks and potential rewards in the search for a new class of drugs to treat complex diseases.
The Addex Therapeutics chart shows how the market values the development of drugs based on allosteric modulators. The Swiss company's market capitalization is a bet on its unique scientific platform for treating neurological disorders. This diagram illustrates how fundamental science is finding its application.
The book value of Swiss Addex Therapeutics is its material basis, consisting of the rights to a unique platform for discovering allosteric modulators and financial reserves for R&D. The chart below shows how this scientific and financial capital has changed.
Addex Therapeutics is a Swiss biopharmaceutical company. Its tangible assets are research laboratories where allosteric modulators are discovered and developed using its unique platform. The chart shows the share of this advanced R&D infrastructure the company controls in its niche.
Addex Therapeutics is a biotechnology company. Pharmaceuticals, as the graph shows, are both knowledge- and capital-intensive. Addex focuses on drug development, and its capital lies in its intellectual property and R&D infrastructure.
Addex's assets are not factories, but a scientific platform based on the discovery of allosteric modulators, which allow for fine-tuning of receptor function for the treatment of neurological diseases. The book value reflects the capital available to support this complex research.
Addex is a Swiss biotech company specializing in allosteric modulators. Its value lies in its unique scientific platform. The chart shows how the market values its partnerships with major pharmaceutical companies.
Addex Therapeutics is a biotech company specializing in developing drugs that modulate receptors rather than block them. Its value is based on its unique scientific platform. The chart shows how investors value this innovative approach.
Addex Therapeutics is a biopharmaceutical company working with receptor modulators. Its unique scientific platform and patent portfolio form the basis of its valuation. This chart illustrates how investors evaluate pharmaceutical technology platforms capable of generating multiple drug candidates.
Addex Therapeutics is a Swiss biotech company developing drugs based on allosteric modulators. This is a complex scientific platform that requires significant investment. This chart shows how the company funds its long-term and risky neuroscience research, which could lead to the development of a new class of drugs.
Addex Therapeutics is a Swiss biotech company developing drugs based on allosteric modulators. This chart shows its financial position at the clinical development stage and its dependence on partnerships and external funding.
Addex Therapeutics is a Swiss clinical-stage biopharmaceutical company. This chart shows its financial structure. As with any biotech without stable revenue, debt is a huge risk, threatening the company's ability to complete its research.
Addex Therapeutics is a Swiss biopharmaceutical company, a pioneer in the development of allosteric modulators—a new class of small-molecule drugs. The chart shows the overall debt burden in the pharmaceutical industry, which helps understand how the company finances its fundamental, yet highly risky and long-term research.
Addex Therapeutics is a Swiss clinical-stage biopharmaceutical company developing drugs for the treatment of neurological disorders. This chart, reflecting the debt of established businesses, emphasizes that Addex's funding is entirely dependent on investors' faith in its scientific platform and partnerships with major pharmaceutical companies.
For Addex Therapeutics, a Swiss biotech, the P/E ratio is irrelevant. The company lacks stable profitability. Its valuation is based on the potential of its scientific platform and partnerships with major pharmaceutical companies that believe in its approach to drug development.
Addex Therapeutics is a clinical-stage pharmaceutical company pioneering the development of small-molecule drugs that act as allosteric modulators for the treatment of neurological disorders. This chart shows the average neuropharmaceutical market value, helping to understand how the market views this cutting-edge scientific platform.
Addex Therapeutics is a Swiss biopharmaceutical company developing drugs for the treatment of neurological disorders. Its valuation depends entirely on the success of its drugs in clinical trials and regulatory approval. Overall market sentiment, reflected in this chart, is completely irrelevant.
Addex Therapeutics is a clinical-stage biopharmaceutical company specializing in the development of small-molecule allosteric modulators for the treatment of CNS diseases. This graph reflects expectations for its partnerships with major pharmaceutical companies and clinical development. The valuation is dependent on the success of its unique scientific platform.
%20P%2FE%20Addex%20Therapeutics&width=1500&height=450&colorIndex=35&v=mr7eoit3.lf-6of3yf4&filename=GURU_Markets_-_Chart-of-the-companys-future-projected-PE-Addex-Therapeutics "Chart of the company's future (projected) P/E Addex Therapeutics")
Addex Therapeutics is a Swiss biopharmaceutical company specializing in the development of small-molecule drugs that modulate receptors. Its valuation relative to other biotech companies reflects investor sentiment about its scientific platform, reflecting how the market views its numerous partnerships with major pharmaceutical companies.
%20P%2FE%20graph%20of%20the%20market%20segment%20-%20&width=1500&height=450&colorIndex=36&v=mr7eoit3.lf-6of3yf4&filename=GURU_Markets_-_Future-projected-PE-graph-of-the-market-segment "Future (projected) P/E graph of the market segment -")
Addex Therapeutics is a Swiss biopharmaceutical company developing allosteric modulator drugs for the treatment of neurological diseases. This approach is complex and innovative. This chart shows the overall risk appetite of investors, which is a key factor in evaluating biotech companies with advanced but not yet commercialized scientific platforms.
%20P%2FE%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=37&v=mr7eoit3.lf-6of3yf4&filename=GURU_Markets_-_Chart-of-the-future-projected-PE-of-the-market-as-a-whole "Chart of the future (projected) P/E of the market as a whole")
Addex Therapeutics is a Swiss clinical-stage biotech company specializing in the development of small-molecule drugs that modulate receptors rather than block them. The financial indicators shown in the graph reflect its neuroscience research expenditures.
Addex Therapeutics is a Swiss biotech company specializing in developing drugs for the treatment of neurological disorders. This chart reflects the financial health of the neuroscience segment of the biotech company, demonstrating how close this highly complex field of medicine is to developing commercially viable drugs.
Addex Therapeutics is a Swiss biopharmaceutical company developing drugs for the treatment of neurological diseases. Its future depends on success in clinical trials and partnerships. This total revenue chart for ADXN is important only from an investment climate perspective.
Addex Therapeutics is a Swiss biotech company developing drugs for the treatment of neurological disorders. Its future profit forecast depends on the success of its clinical trials and partnerships. This chart shows how analysts assess the potential of its scientific platform.
%20profit%20of%20the%20company%20Addex%20Therapeutics&width=1500&height=450&colorIndex=41&v=mr7eoit3.lf-6of3yf4&filename=GURU_Markets_-_Graph-of-future-projected-profit-of-the-company-Addex-Therapeutics "Graph of future (projected) profit of the company Addex Therapeutics")
Addex Therapeutics is a Swiss biopharmaceutical company pioneering the development of small-molecule drugs that modulate G protein-coupled receptors (GPCRs). This graph shows forecasts for the neurosegment. It illustrates how fundamental research can lead to the development of entirely new classes of drugs.
%20profits%20of%20companies%20in%20a%20market%20segment%20-%20&width=1500&height=450&colorIndex=42&v=mr7eoit3.lf-6of3yf4&filename=GURU_Markets_-_Graph-of-future-predicted-profits-of-companies-in-a-market-segment "Graph of future (predicted) profits of companies in a market segment -")
The forecast in this chart determines the investment climate in the biotech sector. Addex Therapeutics, which develops small-molecule drugs, requires stable funding. Economic growth and investor interest in pharmaceuticals are contributing to this. A recession, however, could make it more difficult to raise funds.
%20profits%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=43&v=mr7eoit3.lf-6of3yf4&filename=GURU_Markets_-_Chart-of-future-predicted-profits-of-the-market-as-a-whole "Chart of future (predicted) profits of the market as a whole")
Addex Therapeutics is a Swiss biotechnology company developing drugs for the treatment of neurological disorders. This metric reflects investor assessments of its clinical pipeline and partnerships with major pharmaceutical companies.
Addex Therapeutics is a Swiss biopharmaceutical company specializing in the development of small-molecule drugs that modulate receptors in the brain. This chart shows the average valuation in the neuroscience sector. It helps understand how investors view Addex's unique scientific platform and its potential for treating neurological disorders.
Addex Therapeutics Ltd. is a Swiss clinical-stage biopharmaceutical company specializing in the development of small-molecule drugs that modulate receptors rather than block them. This represents a new approach to pharmacology. The company's valuation is based on the potential of its scientific platform. This chart helps assess the risks involved in innovative biotech.
Addex Therapeutics is a Swiss biopharmaceutical company developing drugs that modulate receptors rather than block them. Future revenue depends on the success of its unique approach. The chart shows the market valuation of its scientific platform and partnerships with major pharmaceutical companies.
%20P%2FS%20Addex%20Therapeutics&width=1500&height=450&colorIndex=47&v=mr7eoit3.lf-6of3yf4&filename=GURU_Markets_-_The-graph-of-the-companys-future-projected-PS-Addex-Therapeutics "The graph of the company's future (projected) P/S Addex Therapeutics")
Addex Therapeutics is a Swiss biotech company pioneering the development of small-molecule drugs that modulate, rather than block, receptors in the brain. This approach may be safer. This chart shows how the market values its unique scientific platform in neuroscience.
%20P%2FS%20market%20segment%20graph%20-%20&width=1500&height=450&colorIndex=48&v=mr7eoit3.lf-6of3yf4&filename=GURU_Markets_-_Future-projected-PS-market-segment-graph "Future (projected) P/S market segment graph -")
This indicator summarizes expectations for the biotech sector. For Addex Therapeutics, a Swiss company developing allosteric modulator drugs, it is a sign of faith in new approaches. Market optimism is helping to fund an innovative approach to targeting receptors for the treatment of neurological diseases.
%20P%2FS%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=49&v=mr7eoit3.lf-6of3yf4&filename=GURU_Markets_-_Chart-of-the-future-projected-PS-of-the-market-as-a-whole "Chart of the future (projected) P/S of the market as a whole")
Addex Therapeutics is a Swiss biopharmaceutical company pioneering the development of small-molecule drugs that modulate receptors rather than block them. This chart reflects revenue from partnerships with major pharmaceutical companies. Future revenue is dependent on the success of clinical trials for drugs to treat neurological disorders.
Addex Therapeutics is a Swiss biopharmaceutical company specializing in the development of small-molecule drugs that modulate receptors rather than block them. This chart shows growth in the neuroscience sector. Addex's unique approach could lead to the creation of safer and more effective drugs for the treatment of CNS diseases.
Addex Therapeutics is a Swiss biopharmaceutical company specializing in drugs for the treatment of central nervous system disorders. Its growth depends on partnerships with major pharmaceutical companies. The overall economic situation, shown in this chart, influences their R&D budgets and willingness to license promising molecules.
Addex Therapeutics is a Swiss biopharmaceutical company specializing in the development of small-molecule drugs that modulate receptors rather than block them. This approach is applied to diseases of the central nervous system. This chart reflects analyst assessments of the company's clinical programs and partnerships.
%20sales%20of%20the%20company%20Addex%20Therapeutics&width=1500&height=450&colorIndex=53&v=mr7eoit3.lf-6of3yf4&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-the-company-Addex-Therapeutics "Schedule of future (projected) sales of the company Addex Therapeutics")
Addex Therapeutics is a biopharmaceutical company specializing in allosteric modulators for the treatment of neurological diseases. This chart shows expectations for the neuroscience sector. It illustrates the scientific interest in new mechanisms of drug action for the treatment of complex brain diseases.
%20sales%20of%20companies%20in%20the%20market%20segment%20-%20&width=1500&height=450&colorIndex=54&v=mr7eoit3.lf-6of3yf4&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-companies-in-the-market-segment "Schedule of future (projected) sales of companies in the market segment -")
Addex Therapeutics Ltd. is a Swiss biopharmaceutical company pioneering the development of small-molecule drugs targeting allosteric modulators. Its value depends on the success of its scientific platform. This graph, reflecting the state of the economy, influences the investment climate and the willingness of large pharmaceutical companies to partner with innovative biotech companies.
%20sales%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=55&v=mr7eoit3.lf-6of3yf4&filename=GURU_Markets_-_Schedule-of-future-predicted-sales-of-the-market-as-a-whole "Schedule of future (predicted) sales of the market as a whole")
Addex Therapeutics is a Swiss biotechnology company specializing in the development of allosteric modulator drugs. This chart shows the financial performance at the clinical partnership stage. Revenue depends on successful milestone payments from the large pharmaceutical companies with which it collaborates on drug development.
Addex Therapeutics is a biopharmaceutical company specializing in the development of small-molecule drugs that modulate receptors in the nervous system. For a company in the research stage, this chart is an important benchmark. It reflects the average profitability in the sector, demonstrating the potential financial return from the successful commercialization of their developments.
Addex Therapeutics is a Swiss biopharmaceutical company specializing in the development of drugs that modulate receptors in the nervous system. This total market profitability chart does not reflect its performance. Its success depends on scientific breakthroughs and the ability to develop new drugs for the treatment of neurological disorders.
Addex Therapeutics is a Swiss biopharmaceutical company pioneering the development of drugs based on allosteric modulators. This graph shows a small scientific team focused on research and partnerships with major pharmaceutical companies.
Addex Therapeutics is a pioneer in the development of small-molecule drugs that modulate rather than block receptors (allosteric modulators). This chart shows the percentage of leading chemists and pharmacologists working in this complex and cutting-edge field the company attracts. It reflects its concentration of unique scientific talent.
Addex Therapeutics is a Swiss biopharmaceutical company specializing in the development of small-molecule drugs that modulate receptor activity rather than block it. This graph illustrates how sophisticated and complex drug design approaches are becoming, requiring chemists and pharmacologists to have a profound understanding of biochemistry.
Addex Therapeutics is a Swiss company working in the field of neuroscience. Its presence in the US capital markets demonstrates that science knows no boundaries. This chart reflects the state of the US labor market, which is a magnet for the best minds and most promising technologies from around the world, enriching it and accelerating innovation.
Addex Therapeutics is a Swiss biotech company specializing in allosteric modulators. This chart represents the net intellectual capital valuation. The company's value is based on its unique scientific platform for drug discovery. The chart shows how highly the market values this scientific toolkit and development pipeline per scientist.
%20of%20the%20company%20Addex%20Therapeutics%20(ADXN)&width=1500&height=450&colorIndex=63&v=mr7eoit3.lf-6of3yf4&filename=GURU_Markets_-_Chart-of-market-capitalization-per-employee-in-thousands-of-dollars-of-the-company-Addex-Therapeutics-ADXN "Chart of market capitalization per employee (in thousands of dollars) of the company Addex Therapeutics (ADXN)")
Addex Therapeutics is a Swiss biotech company specializing in drugs for the treatment of neurological disorders. The chart shows how the market values their scientific platform based on allosteric modulators. This indicates confidence in their unique approach to drug development.
%20by%20market%20segment%20-%20&width=1500&height=450&colorIndex=64&v=mr7eoit3.lf-6of3yf4&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-by-market-segment "Market capitalization per employee (in thousands of dollars) by market segment -")
Addex Therapeutics is a Swiss biopharmaceutical company developing small-molecule drugs. This chart shows the average market capitalization per employee, illustrating how the market values cutting-edge scientific platforms.
%20for%20the%20overall%20market&width=1500&height=450&colorIndex=65&v=mr7eoit3.lf-6of3yf4&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-for-the-overall-market "Market capitalization per employee (in thousands of dollars) for the overall market")
Addex Therapeutics is a Swiss clinical-stage biotech company. The company has no commercial products. This chart shows the net loss per employee. It reflects how much the company invests in each scientist for R&D.
%20Chart%20Addex%20Therapeutics%20(ADXN)&width=1500&height=450&colorIndex=66&v=mr7eoit3.lf-6of3yf4&filename=GURU_Markets_-_Company-Profit-Per-Employee-in-thousands-of-dollars-Chart-Addex-Therapeutics-ADXN "Company Profit Per Employee (in thousands of dollars) Chart Addex Therapeutics (ADXN)")
Addex Therapeutics is a biopharmaceutical company developing drugs based on allosteric modulators for the treatment of neurological disorders. Its value lies in its unique scientific platform. At the clinical trial stage, this graph will likely show negative profit per employee, reflecting the high costs of maintaining a research team.
%20in%20the%20market%20segment%20-%20&width=1500&height=450&colorIndex=67&v=mr7eoit3.lf-6of3yf4&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-in-the-market-segment "Chart of profit per employee (in thousands of dollars) in the market segment -")
Addex Therapeutics (ADXN) is a Swiss clinical-stage biotechnology company specializing in the development of small-molecule drugs (allosteric modulators) for the treatment of neurological disorders. This chart shows the general market standard for profitability per employee. For ADXN (which is currently investing in R&D), this is a benchmark: if successful, their IP will generate profit.
%20for%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=68&v=mr7eoit3.lf-6of3yf4&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-for-the-market-as-a-whole "Chart of profit per employee (in thousands of dollars) for the market as a whole")
Addex Therapeutics is a Swiss clinical-stage biopharmaceutical company working with allosteric modulators. This chart is a glimpse into the future, reflecting revenue potential if its innovative drug discovery approach proves successful and leads to partnerships or product approvals.
&width=1500&height=450&colorIndex=69&v=mr7eoit3.lf-6of3yf4&filename=GURU_Markets_-_Sales-chart-per-company-employee-Addex-Therapeutics-ADXN "Sales chart per company employee Addex Therapeutics (ADXN)")
Addex Therapeutics is a Swiss clinical-stage biotechnology company specializing in allosteric modulators for the treatment of neurological diseases. Revenue is not yet available. This chart shows the average revenue per employee in the segment, which serves as a benchmark for commercial pharmaceutical companies.
Addex Therapeutics is a Swiss clinical-stage biotech company specializing in the development of allosteric modulator drugs. The company has no commercial revenue, which is irrelevant. Its entire value lies in the potential of its R&D platform.
Addex Therapeutics is a Swiss biotech company developing drugs (allosteric modulators) for the treatment of central nervous system diseases. The company has a long history of failures. This chart shows the odds that their current developments will suffer the same fate. "Bears" believe their platform is ineffective, and the company will run out of money.
&width=1500&height=450&colorIndex=72&v=mr7eoit3.lf-6of3yf4&filename=GURU_Markets_-_Short-Shares-Chart-for-the-Company-Addex-Therapeutics-ADXN "Short Shares Chart for the Company Addex Therapeutics (ADXN)")
Addex Therapeutics (ADXN) is a Swiss biopharmaceutical company developing small-molecule drugs (allosteric modulators) for the treatment of central nervous system disorders, such as Parkinson's disease. This chart shows the overall short position in the neuroscience-focused biotech sector. Its rise signals extreme investor skepticism about the success of clinical trials in this challenging area.
Addex (ADXN) is a clinical-stage biotech company. Its survival depends entirely on access to capital markets. When this market pessimism indicator rises, it signals a "venture winter." Investors panic and flee unprofitable biotechs, fearing ADXN won't be able to raise capital.
Addex Therapeutics (ADXN) is a Swiss company developing allosteric modulators, a new class of drugs for the treatment of neurological disorders. This chart measures the rate of price change. It helps identify when investor enthusiasm (above 70) or disappointment (below 30) about partnerships or data peaks.
&width=1500&height=450&colorIndex=75&v=mr7eoit3.lf-6of3yf4&filename=GURU_Markets_-_RSI-14-indicator-chart-for-the-companys-stock-Addex-Therapeutics-ADXN "RSI 14 indicator chart for the company's stock Addex Therapeutics (ADXN)")
Addex Therapeutics is a Swiss biopharmaceutical company specializing in "allosteric modulators," a new class of drugs that fine-tune receptors in the brain to treat neurological disorders. This chart shows the overall momentum in the neuro biotech segment. It helps distinguish the reaction to the ADXN news from general euphoria or industry-wide panic.
Addex Therapeutics (ADXN) is a biotech company. Like everything in its sector, it's critically dependent on this schedule. Market euphoria offers the potential to easily raise hundreds of millions of dollars for research. Market panic risks running out of money before its breakthrough technologies reach patients.
Addex Therapeutics is a Swiss biotech company, a pioneer in allosteric modulators—a new class of drugs for the treatment of central nervous system disorders (Parkinson's, epilepsy). This chart shows the average analyst forecast. Their targets are based on the success of partnerships (for example, with Janssen) and the progress of their internal R&D pipeline.
&width=1500&height=450&colorIndex=78&v=mr7eoit3.lf-6of3yf4&filename=GURU_Markets_-_A-chart-showing-analyst-consensus-forecasts-for-the-expected-stock-price.-ADXN-Addex-Therapeutics "A chart showing analyst consensus forecasts for the expected stock price. ADXN (Addex Therapeutics)")
Addex Therapeutics is a Swiss biotech company specializing in "allosteric modulators," a new class of drugs for the treatment of neurological disorders (Parkinson's). This chart shows how far the current share price differs from the "fair" value predicted by analysts. It reflects their faith in this complex science.
&width=1500&height=450&colorIndex=79&v=mr7eoit3.lf-6of3yf4&filename=GURU_Markets_-_A-chart-showing-the-difference-between-the-consensus-forecast-and-the-actual-stock-price.-ADXN-Addex-Therapeutics "A chart showing the difference between the consensus forecast and the actual stock price. ADXN (Addex Therapeutics)")
Addex Therapeutics is a Swiss biotech company specializing in "allosteric modulators," a new class of drugs for the treatment of neurological disorders (Parkinson's). This chart shows analysts' overall expectations across the neuroscience sector, reflecting the confidence of experts in this sophisticated R&D platform.
Addex Therapeutics (ADXN) is a Swiss biopharmaceutical company. They develop "small molecules" that fine-tune brain receptors rather than block them (allosteric modulators) to treat Parkinson's disease. This chart shows the overall risk appetite, reflecting the market's willingness to fund breakthrough but high-risk R&D platforms.
Addex is a Swiss biotech working on brain regulators. They don't block, but rather modulate (fine-tune) receptors (mGlu) to treat neurological disorders (Parkinson's, epilepsy). This graph is a pure indicator of their R&D. It reflects their (very long) R&D journey and their partnerships with big pharma (Janssen).
Addex Therapeutics (ADXN) is a Swiss biotech company specializing in allosteric modulators. These are smart drugs that fine-tune brain receptors rather than block them, to treat neurological disorders. This chart shows the average index for the segment, helping to assess how this complex scientific platform compares to the average market.
Addex Therapeutics is a Swiss biopharmaceutical company developing allosteric modulators for the treatment of neurological disorders. This chart, which reflects the market average, provides a macro backdrop. It helps assess how ADXN, the scientific platform, compares to overall economic trends.
